Diagnoptics. Non-invasive assesment of cardiovascular risk and risk of diabetes.

Advanced Glycation Endproducts

Advanced Glycation Endproducts play a key role in the development of chronic age-related diseases such as diabetes, renal failure and cardiovascular disease.

Cardiovascular risk

Advanced Glycation Endproducts play a key role in the development of chronic age-related diseases such as diabetes, renal failure and cardiovascular disease.

About Diagnoptics

"Our results show that skin autofluorescence is strongly correlated with the presence and severity of erectile dysfunction (ED) in men with diabetes. AGEs contribute to the pathogenesis of the vascular complications of diabetes, and so measuring levels of these compounds may improve our ability to estimate the risk of complications in diabetic patients with ED." Kouidrat et al (2017); Journal of Diabetes and its complications

AGE Reader App

The AGE Reader App allows you to generate a comprehensive Cardiovascular Risk Report based on the AGE Reader measurement. For each patient all visits can be documented and consulted in the easy to use App.

Download app / Read more »

More information

Request information

Would you like to learn more about our products? Request any information you wish to receive here.

AGE Reader now approved as medical device in Argentina

The AGE Reader has received its market approval from ANMAT in Argentina. “We have been working on this for a long time with our partner IRAOLA in Argentina", says Bart va...

» Read more

The AGE Reader and Diab-spot have received approval in a number of countries. Please check with the distributor in your country or Diagnoptics what the regulatory approval status is in your country. US Caution: Federal law restricts the AGE Reader and Diab-spot system to investigational use only. Commercial distribution has not been granted by the US FDA. Please see the AGE Reader and Diab-spot user manuals for descriptions of all relevant warnings, cautions, contraindications and safety information.